OBJECTIVES: To assess the impact of urinary disorders on multiple sclerosis (MS) patients' health-related quality of life and to examine the cross-sectional construct validity of Qualiveen, a questionnaire originally developed for spinal cord injury patients with urinary disorders, in patients with MS. DESIGN: Cohort study. SETTING: Neurourodynamic units in 3 French university hospitals. PARTICIPANTS: Patients with MS (N=197). INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: We tested predictions about the relationships among clinical features, the French version of the Multiple Sclerosis Quality of Life questionnaire (SEP-59), the Expanded Disability Status Scale (EDSS), and the 4 domains of the 30-item Qualiveen. RESULTS: Cross-sectional correlations among the 4 Qualiveen domains and type (range, .36-.54), number of symptoms (range, .23-.50), and severity of incontinence (.39-.68) were generally moderate to strong. The SEP-59 bowel and bladder function domain showed moderate to strong relationships with the Qualiveen (range, .39-.59). Relationships with other SEP-59 domains were generally weak (range, .22-.35), and with the EDSS they were very weak. Predictions proved generally accurate (weighted kappa=.61). CONCLUSIONS: Our data supported the Qualiveen's validity as a discriminative instrument for use with patients with MS. Further studies should explore the Qualiveen's longitudinal validity and responsiveness.
OBJECTIVES: To assess the impact of urinary disorders on multiple sclerosis (MS) patients' health-related quality of life and to examine the cross-sectional construct validity of Qualiveen, a questionnaire originally developed for spinal cord injurypatients with urinary disorders, in patients with MS. DESIGN: Cohort study. SETTING: Neurourodynamic units in 3 French university hospitals. PARTICIPANTS: Patients with MS (N=197). INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: We tested predictions about the relationships among clinical features, the French version of the Multiple Sclerosis Quality of Life questionnaire (SEP-59), the Expanded Disability Status Scale (EDSS), and the 4 domains of the 30-item Qualiveen. RESULTS: Cross-sectional correlations among the 4 Qualiveen domains and type (range, .36-.54), number of symptoms (range, .23-.50), and severity of incontinence (.39-.68) were generally moderate to strong. The SEP-59 bowel and bladder function domain showed moderate to strong relationships with the Qualiveen (range, .39-.59). Relationships with other SEP-59 domains were generally weak (range, .22-.35), and with the EDSS they were very weak. Predictions proved generally accurate (weighted kappa=.61). CONCLUSIONS: Our data supported the Qualiveen's validity as a discriminative instrument for use with patients with MS. Further studies should explore the Qualiveen's longitudinal validity and responsiveness.
Authors: Denise G Tate; Tracey Wheeler; Giulia I Lane; Martin Forchheimer; Kim D Anderson; Fin Biering-Sorensen; Anne P Cameron; Bruno Gallo Santacruz; Lyn B Jakeman; Michael J Kennelly; Steve Kirshblum; Andrei Krassioukov; Klaus Krogh; M J Mulcahey; Vanessa K Noonan; Gianna M Rodriguez; Ann M Spungen; David Tulsky; Marcel W Post Journal: J Spinal Cord Med Date: 2020-03 Impact factor: 1.985
Authors: E Castel-Lacanal; X Gamé; X De Boissezon; J Guillotreau; E Braley-Berthoumieux; C Terracol; D Gasq; M Labrunee; F Viala; P Rischmann; M Clanet; P Marque Journal: World J Urol Date: 2013-01-06 Impact factor: 4.226
Authors: Giuseppe Quarto; Riccardo Autorino; Antonio Gallo; Marco De Sio; Massimo D'Armiento; Sisto Perdonà; Rocco Damiano Journal: Int Urogynecol J Pelvic Floor Dysfunct Date: 2006-05-13
Authors: Véronique Bonniaud; Dianne Jackowski; Bernard Parratte; Rick Paulseth; Sharon Grad; Peter Margetts; Gordon Guyatt Journal: Qual Life Res Date: 2005-03 Impact factor: 4.147
Authors: Lisa A Merenda; Theresa Duffy; Randal R Betz; Mary Jane Mulcahey; Gregory Dean; Michel Pontari Journal: J Spinal Cord Med Date: 2007 Impact factor: 1.985